Key result
The combination of quercetin and candesartan significantly restored cardiac biomarkers and antioxidant profiles to normal in doxorubicin-treated rats, showing greater cardioprotection than either alone.
Why the study?
Doxorubicin is a potent anti-cancer agent whose prolonged use generates free radicals leading to dose-dependent cardiac toxicity, prompting exploration of protective strategies.
Does the combination of candesartan and quercetin prevent doxorubicin-induced cardiotoxicity in rats?
Does the combination of candesartan and quercetin prevent doxorubicin-induced cardiotoxicity in rats?
The combination of quercetin and candesartan demonstrates synergistic cardioprotective effects against doxorubicin-induced cardiomyopathy in a rat model.
No takes yet. Share an insight, caveat, or question.
Animal findings on cardioprotection against doxorubicin remain preliminary; leaves open any clinical translation pending human trials.
Majhi et al. (2022) studied Doxorubicin-induced cardiotoxicity. Candesartan and quercetin vs. Doxorubicin alone was evaluated on Cardiac biomarkers, lipid profile, and antioxidant levels. The combination of quercetin and candesartan significantly restored cardiac biomarkers and antioxidant profiles to normal in doxorubicin-treated rats, showing greater cardioprotection than either alone.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: